MDMA (Ecstasy, Molly) and Ketamine Therapy | Tovani Health
Ecstasy (MDMA) (also: Molly) — Serotonergic releaser / stimulant (DEA Schedule I)
Verdict at Tovani Health
Federally illegal; pharmacologically compatible with adequate spacing, but we will not run a session in proximity to use.
MDMA is a DEA Schedule I controlled substance in the United States, meaning federal law treats it as having no accepted medical use and high abuse potential. That legal status alone shapes what we can do. Pharmacologically, the data is more nuanced: there are no documented case reports of serotonin syndrome from MDMA combined specifically with ketamine in the published literature. The combination-harm evidence extrapolates from MDMA plus SSRIs and MAOIs, where serotonin syndrome and deaths are well documented. Our position: we will not run a ketamine session while MDMA is on board or in the recovery window. We do not categorically refuse patients who have used MDMA recreationally with adequate separation. We discuss timing, frequency, and the patient's overall pattern individually.
If you take Ecstasy regularly and are considering at-home ketamine therapy, the combination is depends on your specific situation. This page covers the brief pharmacologic context and what we do at intake.
How Ecstasy interacts with ketamine
MDMA causes massive serotonin release via SERT reversal, with additional dopamine and norepinephrine release. Ketamine has small serotonergic activity but produces transient sympathomimetic activation. The two stack on cardiovascular load (BP, HR, hyperthermia) more reliably than on serotonin syndrome. The pharmacologic window for clinical interaction is roughly the duration of MDMA's active effect plus a few half-lives, typically 24 to 72 hours.
What we do at intake
Disclose any recent or planned MDMA use. We ask for a minimum 2-week separation between any MDMA exposure and a ketamine session, both as a pharmacologic buffer and because using a Schedule I substance in the active window of a clinical session is something we cannot supervise. We are not an enforcement service and will not report disclosed use; honest answers let us plan safely.
Bottom line
MDMA is a DEA Schedule I controlled substance in the United States, meaning federal law treats it as having no accepted medical use and high abuse potential. That legal status alone shapes what we can do. Pharmacologically, the data is more nuanced: there are no documented case reports of serotonin syndrome from MDMA combined specifically with ketamine in the published literature. The combination-harm evidence extrapolates from MDMA plus SSRIs and MAOIs, where serotonin syndrome and deaths are well documented. Our position: we will not run a ketamine session while MDMA is on board or in the recovery window. We do not categorically refuse patients who have used MDMA recreationally with adequate separation. We discuss timing, frequency, and the patient's overall pattern individually.
Frequently Asked Questions
Can I do MDMA-assisted therapy and KAP together?
Not in the same protocol. They are complementary in principle but should not be combined acutely. We can coordinate sequentially with an MDMA-assisted therapist.
Ready to find out if at-home ketamine fits your situation?
We’ll note that you’re on Ecstasy (MDMA) at intake. The eligibility check takes 5 minutes and gives you an honest answer about whether at-home ketamine fits your specific situation.
FL and NJ residents only. Benjamin Soffer, DO — Tovani Health.
Sources
The verdict and clinical guidance on this page are based on the following peer-reviewed literature and FDA prescribing information.
- Qualitative review of serotonin syndrome, ecstasy (MDMA) and the use of other serotonergic substances: hierarchy of risk. Silins E, Copeland J, Dillon P. Australian and New Zealand Journal of Psychiatry. 2007. PMID: 17620161
Reviews MDMA serotonin syndrome cases and stratifies combination risk with other serotonergic agents. No ketamine-specific cases reported.
- Psychedelics. Nichols DE. Pharmacological Reviews. 2016. PMID: 26841800
Landmark pharmacology review covering MDMA, LSD, psilocybin mechanisms.
Clinically reviewed
Reviewed by Benjamin Soffer, DO on May 16, 2026. Dr. Soffer is a board-certified physician (American Board of Internal Medicine) licensed in Florida and New Jersey, prescribing at-home ketamine therapy through Tovani Health.
This page is general information about how this medication interacts with at-home ketamine therapy at Tovani Health. It is not a substitute for medical advice from your prescribing physician about your specific situation. Always discuss medication changes with the doctor who prescribed them.